Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.

JNJ-38877605 is an ATP-competitive inhibitor of c-Met.

PF-04217903 is a selective ATP-competitive c-Met inhibitor.

Capmatinib is a novel, ATP-competitive inhibitor of c-MET.

Linsitinib is an orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR.

GSK1904529A is a selective inhibitor of IGF-1R and IR.

NVP-ADW742 is an IGF-1R inhibitor.